Result of AGM

AOTI, Inc.

21 May 2026

 

21 May 2026

AOTI, Inc. (the "Company" or "Group" or "AOTI")

Result of Annual General Meeting

The Annual General Meeting of AOTI, Inc. was held at the offices of Burges Salmon, 6 New St Square, London, EC4A 3BF on 21 May 2026 at 10:00 a.m.

All 12 resolutions put to members were passed on a poll. Resolutions 1 to 11 were passed as ordinary resolutions and Resolution 12 was passed as a special resolution.

The number of votes cast for and against each of the resolutions proposed, and the number of votes withheld were as follows:

Resolution	Votes for	%	Votes against	%	Votes withheld
Resolution 1 (Ordinary) To receive the Company's annual report and accounts for the year ended 31 December 2025, together with the Directors' and Auditor's Report thereon.	71,546,968	100.00	0	0.00	891,488
Resolution 2 (Ordinary) To approve the Directors' Remuneration Report for the year ended 31 December 2025.	72,290,728	99.80	147,728	0.20	0
Resolution 3 (Ordinary) To approve the Directors' Remuneration Policy for the year ended 31 December 2025.	72,290,728	99.80	147,728	0.20	0
Resolution 4 (Ordinary) To re-appoint Douglas Le Fort as a director of the Company.	71,564,669	98.79	873,787	1.21	0
Resolution 5 (Ordinary) To re-appoint Michael Griffiths as a director of the Company.	72,438,456	100.00	0	0.00	0
Resolution 6 (Ordinary) To re-appoint Anthony Bourne as a director of the Company.	72,290,728	99.80	147,728	0.20	0
Resolution 7 (Ordinary) To re-appoint Richard Cotton as a director of the Company.	72,438,456	100.00	0	0.00	0
Resolution 8 (Ordinary) To re-appoint Ceri Morgan as a director of the Company.	72,438,456	100.00	0	0.00	0
Resolution 9 (Ordinary) To re-appoint Jayesh Pankhania as a director of the Company.	72,438,456	100.00	0	0.00	0
Resolution 10 (Ordinary) To re-appoint Grant Thornton (Ireland) as auditor of the Company.	72,438,456	100.00	0	0.00	0
Resolution 11 (Ordinary) To authorise the Directors to determine the fees payable to the auditor.	72,438,456	100.00	0	0.00	0
Resolution 12 (Special) To disapply statutory pre-emption rights for the purpose of financing or refinancing a transaction.	72,290,728	99.80	147,728	0.20	0

As at 21 May 2026, there were 106,359,163 ordinary shares in issue. Shareholders are entitled to one vote per share. Votes withheld are not votes in law and so have not been included in the calculation of the proportion of votes for and against a resolution.

The full text of each resolution is available in the Notice of Annual General Meeting, published on our website.

ENDS

AOTI, INC. Dr. Mike Griffiths, Chief Executive Officer Jayesh Pankhania, Chief Financial Officer	[phone] [e-mail]
Peel Hunt LLP (Nominated Adviser and Joint Broker) Dr. Christopher Golden, James Steel	[phone]
Panmure Liberum Limited (Joint Broker) Emma Earl, Will Goode, Mark Rogers Rupert Dearden	[phone]
FTI Consulting (Financial PR & IR) Ben Atwell, Simon Conway, Natalie Garland-Collins	[phone] [e-mail]

ABOUT AOTI, INC.

AOTI, INC. was founded in 2006 and is based in Oceanside, California, US and Galway, Ireland, providing innovative solutions to resolve severe and chronic wounds worldwide. Its products reduce healthcare costs and improve the quality of life for patients with these debilitating conditions. The Company's patented non-invasive Topical Wound Oxygen (TWO₂^®) therapy has demonstrated in differentiating, robust, double-blinded randomized controlled trials (RCT) and real-world evidence (RWE) studies to more-durably reduce the recurrence of Diabetic Foot Ulcers (DFUs), resulting in an unprecedented 88 per cent reduction in hospitalizations and 71 per cent. reduction in amputations over 12 months. TWO₂^® therapy can be administered by the patient at home, improving access to care and enhancing treatment compliance. TWO₂^® therapy has received regulatory clearance from the US (FDA), Europe (CE Mark), UK (MHRA), Health Canada, the Chinese National Medical Products Administration, Australia (TGA) and in Saudi Arabia. TWO₂^® therapy has also recently received positive coverage recommendations from the Federal Joint Committee (G-BA) in Germany and National Institute for Health and Care Excellence (NICE) in the United Kingdom. Also see www.aotinc.net

 

END